This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Sickle Cell Disease
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
Lucile Packard Children's Hospital at Standford, Palo Alto, California, United States, 94304
Mayo Clinic Florida, Jacksonville, Florida, United States, 32224
University of Miami, Miami, Florida, United States, 33136-1005
Boston Children's Hospital, Boston, Massachusetts, United States, 02215
Henry Ford Cancer Center, Detroit, Michigan, United States, 48202
University of Minnesota, Minneapolis, Minnesota, United States, 55455
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States, 63110
Columbia University Irving Medical Center, New York, New York, United States, 10032
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 35 Years
ALL
No
Beam Therapeutics Inc.,
2027-02-01